US Biopharmaceuticals: Reviewing current payer dynamics and key debates, KOL call Fri, 06/12 @ 11am ET

Research evidence excerpt

US Biopharmaceuticals: Reviewing current payer dynamics and key debates, KOL call Fri, 06/12 @ 11am ET

Accessible version

US Biopharmaceuticals

Reviewing current payer dynamics and key

debates, KOL call Fri, 06/12 @ 11am ET

Invitation

Topic 08 June 2026

While policy-related pricing headwinds have arguably eased, reimbursement and access Equity

dynamics continue to drive Biopharma—particularly as a new wave of novel (e.g., United States

Brensupri, Revuforj/ Komzifti, Rezdiffra, Leqembi) and next-gen agent launches Biopharmaceuticals

(e.g., Attruby, Myqorzo, Filspari) shape commercial expectations and competitive

Related Researchpositioning across our coverage. As access, utilization, and segment penetration

continue to evolve, we are hosting a payer KOL to discuss: (1) the current pricing and Insmed Incorporated: Thoughts from our

access backdrop; (2) key ongoing debates; (3) the scope for differentiation to influence Vegas healthcare conference investor dinner

decision-making; and (4) product- and indication-specific dynamics on Friday, June

12th at 11am ET. We hope you can join us. US Biopharmaceuticals: Revisiting the menins:

BrandImpact trends favorable ahead of

Host Speaker(s) Date and Time encouraging EHA/ASCO

Jason Zemansky, SMid cap Biotech Friday, June 12, 2026 11:00 AM Eastern Time BridgeBio Pharma: Thoughts from our Vegas

Analyst, BofA Global Research healthcare conference fireside and investor

Audio Information dinner

Guest Speaker(s) This call requires a personal identification

Joel Brill, MD Chief Medical Officer number (PIN) for each participant to join. Cytokinetics, Incorporated: Initial metrics encouraged, but still much to sort out post-

of Predictive Health, which focuses Retrieve your PIN and view the event dial-in ACACIA; thoughts post 1Q